Introduction
Cancer is an uncontrolled proliferation of cells and has become a public health concern all over the world.
Cancer cells have the ability to invade through blood or lymph and spread to other parts of the body.
1 Cancer can affect almost every tissue in the body and is one of the major causes of mortalities each year. 2 According to the World Health Organization, about 8.8 million deaths were reported due to cancer in 2015. 3 Deaths due to cancer are increasing continuously and it is estimated that about thirteen million people will die of cancer in 2030. 4, 5 Chemotherapy is one of the important methods for the treatment of cancer besides surgery and radiation therapy. There are many effective cytotoxic drugs available for the treatment of cancer, but their lower selectivity for tumor cells than normal cells is responsible for severe adverse effects. 6 Chemotherapeutic agents are now used in combination so that the toxicity due to the overexpression of single agents can be prevented.
a need to summarize the research publications in the field. This article comprehensively deals with the recent research work on piperazine derivatives having anticancer activity and highlights the structural parameters responsible for their bioactivity.
Review of the literature

FDA-approved piperazine-based anticancer drugs
The piperazine ring is present in a number of FDA-approved anticancer agents. More than 200 approved anticancer agents by National Cancer Institute USA were checked; among these, the piperazine-based anticancer agents include abemaciclib 1, bosutinib 2, brigatinib 3, dexrazoxane 4, dosatinib 5, imatinib 6, leucovorin 7, olaparib 8, palbociclib 9, ponatinib 10, rociletinib 11, venetoclax 12, and trabectidin 13 ( Figure 1 ).
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Abemaciclib 1 was reported as a D-cyclin dependent kinase (CDK4/6) inhibitor to treat different cancer types. 21 Bosutinib 2 was found effective for the cure of breast cancer 22 while brigatinib 3 is effective against oncogenic anaplastic lymphoma kinase. 23 Bates and coworkers described the use of dexrazoxane 4 in stage IIIB or IV of metastatic breast cancer as a cost-effective treatment preventing anthracycline-induced cardiotoxicity.
24
Dasatinib 5 is an orally active drug for the treatment of chronic myelogenous leukemia and acute lymphoblastic leukemia, 25 and imatinib 6 is a potential protein kinase inhibitor. 26 Leucovorin 7 plus fluorouracil is used for the cure of colon cancer. 27 Olaparib 8 is applicable in ovarian and breast cancer treatment 28 and palbociclib 9 in combination with endocrine agents is approved for treatment of patients with estrogen receptor-positive breast cancer. 29, 30 Ponatinib 10 is an excellent inhibitor of RET kinase and has activity in models of RET-driven medullary thyroid carcinoma. 31 Rociletinib 11 is an effective inhibitor of epidermal growth factor receptor (EGFR) and is effective against non-small-cell lung cancer. 32 Venetoclax 12 and trabectidin 13 are effective for the treatment of chronic lymphocytic leukemia 33 and liposarcoma or leiomyosarcoma, respectively. 
Chemistry and pharmacology of new piperazine-containing anticancer compounds
Piperazine derivatives with anticancer activities are categorized below on the basis of their chemical structures.
Piperazine-containing polymeric anticancer agents
In 2016, organo-iron complexes containing 1,4-dipiperazinobenzene-cyclopentadienyliron hexafluorophosphate were synthesized and were evaluated against two breast cancer cell lines, HTB26 and MCF7. Compound 14 ( Figure 2 ) exhibited prominent activity against the HTB26 and MCF7 cell lines, having IC 50 values of 14 µM for both. 35 In the same year, the same authors synthesized organo-iron melamine dendrimers capped with piperazine molecules. The anticancer activity of the dendrimers was evaluated and significant efficacy was observed for piperazine-terminated organo-iron dendrimers against HTB26 and MCF7 cancer cell lines with IC 50 values of 3.6 µM and 2.5 µM, respectively. Piperazine-terminated dendrimers exhibited significant inhibitory activities as compared to the dendrimers having chloro or hydroxy terminal groups. 
Metal complexes of piperazine derivatives
The metal-containing anticancer drugs cisplatin and carboplatin are effective in the treatment of testicular, ovarian, and colorectal cancer. lines. This compound also showed prominent telomerase inhibitory activity, having an IC 50 value of 17.1 µM.
39
Heteroleptic palladium(II) complexes of 4-(2-methoxyphenyl)piperazine 1-dithiocarbamates with diphenyl-ptolylphosphine and tri-p-tolylphosphine (16 and 17) were prepared. Compound 16 exhibited promising cytotoxic activity against MCF7, having an IC 50 value of 9.1 ± 2.3 µM. Compound 17 showed prominent activity in this series, having an IC 50 value of 2.3 ± 0.2 µM against MDA-MB-231. The higher activity of compound 17 was possibly due to its higher stability as compared to 16, as determined by density functional theory. 40 Arjmand et al. designed and synthesized tin iminodiacetate conjugated with piperazinediium cation 18 as a potential antitumor agent. Conjugate 18 showed significant cytotoxic activity versus HCT15, HOP62, MCF7, and SK-OV-3 cancer cell lines, having GI 50 values of less than 10 µg/mL. It also inhibited topoisomerase-1, having an IC 50 value of 30 µM. The new complex showed less systemic toxicity on the livers and kidneys of rats. This compound interacted with c-DNA through electrostatic interaction. 41 The conjugates of thiosemicarbazonepiperazine and thiosemicarbazone-morpholine along with their copper(II) complexes were studied as anticancer agents. Compound 19b showed activity against LS174 (colon cancer) cancer cells, having IC 50 values of 16.4 ± 4.2 µM. The compounds without the metal complexation showed no anticancer activity, having IC 50 values of greater than 300 µM. 42 The coordination complexes of indoloquinoline-methyl piperazine hybrids with ruthenium and osmium metal were evaluated for their cytotoxic activity. The position of metal complexes with indoloquinoline-piperazine was altered to see the effect on water solubility and anticancer activity. Varchi et al. designed and synthesized a molecular conjugate consisting of a photosensitizer (pheophorbide a) and it was attached to a piperazine containing an antiandrogen molecule via a small pegylated linker.
Compound 36 ( Figure 5 ) showed good activity against the PC3 cell line, having an IC 50 value of 35.1 nM upon irradiation of cells with white light and 98 nM when irradiated with red light. This is due to the reactive oxygen species generated by the photosensitizer part after light irradiation while the antiandrogen molecule releases nitric oxide to produce the overall phototoxic effect. This approach is very interesting and should be developed further. 54 Yang et al. reported the synthesis of cyclic polyamine dehydroabietylamine derivatives and evaluated in vitro anticancer activity against MCF7 and HepG-2 (liver carcinoma) cancer cell lines while using 5-fluorouracil as a standard drug. Piperazine-containing compound 37 was found to have good tumor inhibition effects on HepG-2, having an IC 50 value of 23.56 µM, and showed selectivity for this cell line compared to MCF7 cells having an IC 50 value of 62.55 µM. The addition of a benzene ring as a linker in these conjugates led to the formation of less active compounds. 55 Mustafa et al. carried out the synthesis of N1-(coumarin- . This compound was also found to be selective as it showed less toxicity to normal human cell lines, which is encouraging for drug development. Therefore, the combination of piperidine acetyl and 4-substituted benzene significantly increased the activity of the derivatives. 
Structural hybrids of piperazine with other pharmacophores
Molecular hybridization is a technique in which two or more pharmacophores are attached by a chemical bond. Natural or synthetic bioactive compounds can be combined to produce new molecules with increased activity and less toxicity. The technique of hybrid molecules is also being used while synthesizing new derivatives.
62 Among the series of novel phenanthridinylpiperazinetriazole hybrid molecules, compound 51 has shown promising activity against the THP1 (human acute monocytic leukemia) cell line, having IC 50 values of 9.73 ± 4.09 µM, while compound 52 was most potent against HL60 (human promyelocytic leukemia), having IC 50 values of 7.22 ± 0.32 µM as compared to the standard drug etoposide (14.10 ± 0.54 µM). Therefore, the introduction of an aryl sulfonyl group to the triazole ring significantly improved the anticancer activities of these derivatives ( Figure 6 ). 63 The hybrid molecules of 4-piperazinylquinoline-derived isatin compounds, 53 and 54 ( Figure 6 ), exhibited prominent activity and caused apoptosis of MCF7 cancer cells, having GI 50 values of 15.12 ± 0.34 and 21.56 ± 0.69 µM, respectively, but not to MCF10A noncancer cells. The lipophilic group at the isatin ring produced more active compounds while the trifluoromethyl group at position #7 of quinoline produced less active compounds as compared to the chloride or bromide group. 64 Murty et al. synthesized a series of piperazinylbenzothiazole/benzoxazole derivatives, which were attached to 1,3,4-oxadiazole-2-thiol via propyl chain. Compound 55, having an IC 50 value of 36.9 µM, was most prominent against the A431 (skin) cell line.
Compound 55 was also active against the MCF7 cell line with an IC 50 value of 52.7 µM but the most potent (human mammary epithelial cell) cell line, having an IC 50 value of greater than 100 µM. 75 Gurdal et al.
synthesized novel benzhydrylpiperazinecarboxamide and thioamide derivatives. 4-Chlorobenzhydryl derivatives were more active as compared to the unsubstituted and disubstituted benzhydryl derivatives. Thioamide derivatives were also more potent than carboxamide derivatives (Figure 8 Among S and N alkyl piperazine derivatives of mercapto-1,2,4-triazole derivatives (Figure 9 ), compounds 98, It was also observed that the compounds with chloro groups at the 3rd and 4th positions of the phenyl ring of the triazole ring and piperazine group substituted with N-3 chlorophenyl, N -2-pyrimidyl, and N -2-pyridyl groups were most active. against the HCT116 cell line was 111, having an IC 50 value of 6.38 µM. Attachment of a disubstituted benzyl group to piperazine produced more active derivatives as compared to the monosubstituted benzyl group. values of 2.73 ± 0.18 and 1.60 ± 0.37 µM, respectively, and it was better than the control drug, amonafide. also carried out and were in accordance with experimental results. 
Conclusion
Piperazine is a part of many natural and synthetic molecules that exhibit significant pharmacological properties. Piperazine is also a main pharmacophore of many drugs under development. In the present review anticancer properties of piperazine-containing molecules have been discussed. Organo-iron complexes linked via piperazine and organo-iron melanin dendrimers having piperazine showed anticancer activities against breast cancer cell lines. Metal complexes such as copper, tin, palladium, ruthenium, and osmium with piperazinecontaining organic compounds also displayed anticancer activities. Copper complexes linked via piperazine and tin complexes with piperazine were found to be the inhibitors of telomerase and topoisomerase-1, respectively. Plant-derived natural molecules such as chalcones, alkaloids, terpenes, coumarins, and constituents of essential oil have potential anticancer activities. Hybrid molecules of these phytochemical compounds with substituted and unsubstituted piperazines demonstrated excellent anticancer activities. Some piperazine conjugates with natural molecules such as β -elemene and pheophorbide produced anticancer activities by the release of reactive oxygen species and nitric oxide molecules. Piperazine was used as a linker in some new anticancer compounds derived from natural substances, such as beta carbolines and pyrrolobenzodiazepines. Piperazine was also used as a linker/bridge between hybrid molecules of quinolines-isatins and phenanthridine-triazoles. Piperazine was a terminal substituent in dihydropyridines, diphenylpyrimidines, diphenyl amine, thienylamidrazones, and thiazolidinone pyridine derivatives with promising anticancer activities. Some highly active anticancer compounds have been produced in which piperazine served as a part of the main pharmacophore. Benzhydrylpiperazine, cyclohexylpiperazine, piperazinehydroxamate, and piperazine-containing alkyl compounds are examples of these derivatives. Condensed heterocyclic derived compounds having piperazine also displayed anticancer activities. These rings are benzothiazole, triazolopyrimidine, pyridopyrimidine, quinoxaline, quinoxaline di-n-oxide, quinazolinone, and naphthalimide. There are many cytotoxic heterocyclic molecules tethered with piperazine. In this review some recent research in the field of synthesis of anticancer piperazine derivatives has been summarized. It can provide useful information for future research in this area.
